8 sgb v for drug reviparin
, atc b01ab08, for the period from 01.
Lastly, Wirth and coworkers (9) randomized 262 patients undergoing elective knee arthroscopy to receive either no treatment or reviparin
once daily subcutaneously for 7 to 10 days.
One clinical trial using reviparin
, a low molecular weight heparin, demonstrated superiority to unfractionated heparin in reducing thrombus size for patients with DVT (Breddin, Hach-Wunderle, Nakov, & Kakkar, 2001).
20] evaluated a total of 1137 patients with DVT who were randomly assigned to UFH or reviparin
for 5-7 days.
The third RCT evaluated reviparin
(another European LMWH) vs placebo in 440 outpatients with lower limb injuries, of whom 293 had fractures.
NEW ORLEANS -- Antithrombotic treatment, in the form of the low-molecular-weight heparin reviparin
, has been shown for the first time to safely improve the outcomes of patients with an acute myocardial infarction.
But the value of adding reviparin
or a similar agent remains in doubt when patients are treated with the fibrin-specific drugs typically used for thrombolysis in the United States, such as alteplase (tissue plasminogen activator), reteplase, and tenecteplase.
The use of the low-molecular-weight heparins (LMWHs) dalteparin, enoxaparin, nadroparin, reviparin
, and tinzaparin resulted in only one vertebral fracture in 486 pregnancies at 21 centers in one study reviewed.
Participants were assigned to one of three treatment regimens: intravenous administration of unfractionated heparin; subcutaneous administration of a low-molecular-weight heparin, reviparin
, twice a day for 1 week; or subcutaneous administration of reviparin
once a day for 4 weeks.
A recent investigation compared subcutaneous LMW heparin and standard intravenous heparin in symptomatic patients suffering from acute DVT Intravenous standard heparin was administered to one group and reviparin
, a LMW heparin, was subcutaneously administered twice daily to another group of DVT patients.
Dalteparin, darbepoetin, dasatinib, dexamethasone + neomycin sulphate + polymyxin B sulfate, epoetin beta, epoetin theta, epoetin zeta, erlotinib, estradiol + cyproterone, etoricoxib, everolimus, follitropin beta, formoterol + beclomethasone, fusidic + betamethasone, fusidic + hydrocortisone , goserelin, hydromorphone hydrochloride, ketorolac, levothyroxine + liothyronine, Linezolid, nadroparin, paliperidone palmitate, pazopanib, pegfilgrastim, piribedil, progesterone, prothipendyl, Reviparin
, risperidone, sildenafil, sumatriptan, tinzaparin, tobramycin, tobramycin + dexamethasone, voriconazole.
LMWH preparations evaluated were certoparin, dalteparin, enoxaparin, nadroparin, reviparin
, and tinzaparin.